According to Roche's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.24505. At the end of 2022 the company had a P/S ratio of 3.79.
Year | P/S ratio | Change |
---|---|---|
2022 | 3.79 | -27.59% |
2021 | 5.23 | 15.69% |
2020 | 4.52 | 3.85% |
2019 | 4.35 | 19.49% |
2018 | 3.64 | -7.15% |
2017 | 3.93 | -0.43% |
2016 | 3.94 | -19.42% |
2015 | 4.89 | 1.4% |
2014 | 4.82 | 6.83% |
2013 | 4.52 | -28.62% |
2012 | 6.33 | 94.73% |
2011 | 3.25 | 29.52% |
2010 | 2.51 | -20.06% |
2009 | 3.14 | 1.44% |
2008 | 3.09 | -16.77% |
2007 | 3.72 | -16.87% |
2006 | 4.47 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | 4.03 | 24.34% | ๐บ๐ธ USA |
![]() Novartis NVS | 3.93 | 21.02% | ๐จ๐ญ Switzerland |
![]() Pfizer PFE | 2.33 | -28.35% | ๐บ๐ธ USA |
![]() Abbott Laboratories ABT | 4.12 | 27.00% | ๐บ๐ธ USA |
![]() Amgen AMGN | 5.41 | 66.80% | ๐บ๐ธ USA |
![]() Sanofi SNY | 2.75 | -15.16% | ๐ซ๐ท France |
![]() Becton Dickinson BDX | 3.94 | 21.48% | ๐บ๐ธ USA |
![]() Merck MRK | 4.52 | 39.39% | ๐บ๐ธ USA |
![]() GlaxoSmithKline GSK | 2.16 | -33.32% | ๐ฌ๐ง UK |